US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery

Key Takeaways

• Expanding demand for advanced drug delivery and containment solutions, driven by trends in biologics, self-administration, and pharmaceutical industry investments, is boosting Stevanato's revenue and growth prospects.
  
• Investments in manufacturing capacity and innovation, alongside regulatory-driven market dynamics, are supporting higher margins, pricing power, and improved earnings quality.
  
• Rising operational costs, regulatory risks, customer concentration, and shifting industry dynamics threaten margin stability and long-term demand for Stevanato's core products.

Catalysts

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

• The growing prevalence of biologics and novel drug classes (including GLP-1s, mAbs, and biosimilars) is driving robust, increasing demand for Stevanato's high-value containment and delivery solutions-evidenced by high growth rates in these product lines and strong order pipelines from major pharma clients-which supports ongoing revenue expansion.
  
• Rising pharmaceutical industry investment in U.S. onshoring and manufacturing capacity creates a structural tailwind for Stevanato's North American operations, particularly at the new Fishers facility; this enhances supply chain localization, deepens client relationships, and is expected to materially contribute to future top-line growth and operating margins as these plants scale up.
  
• Secular shifts toward self-administration and personalized medicine are accelerating demand for specialized, integrated drug delivery devices (e.g., auto-injectors, pen injectors, and dual/chamber syringes)-areas where Stevanato is expanding capacity and capability, suggesting greater future revenue mix from higher-margin solutions and sustained margin expansion.
  
• Scaling commercial production at the Latina and Fishers greenfield sites, along with business optimization and increased mix of high-value solutions, is expected to unlock meaningful operating leverage as utilization ramp-up reduces margin dilution and supports consolidated gross margin and EBITDA margin improvements over the next several years.
  
• Increased regulatory requirements for drug safety and traceability are leading pharma customers to prefer proven, innovative suppliers like Stevanato for premium, compliant packaging and delivery systems, which supports pricing power and margin resilience even in the face of rising compliance costs, thus safeguarding future earnings quality.

Stevanato Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Stevanato Group's revenue will grow by 9.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 11.8% today to 15.9% in 3 years time.
• Analysts expect earnings to reach €244.0 million (and earnings per share of €0.9) by about April 2029, up from €139.8 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 31.9x on those 2029 earnings, up from 26.0x today. This future PE is lower than the current PE for the US Life Sciences industry at 33.8x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 10.43%, as per the Simply Wall St company report.

Risks

• Rising costs from ongoing capital investments in facilities (Fishers, Latina) and persistent negative free cash flow-even as gross margins expand-could pressure net margins if scaling and margin enhancement in these sites take longer than planned or face operational setbacks.
  
• Increased tariffs on EU-to-U.S. imports and heightened global regulatory scrutiny may necessitate aggressive price negotiations or cost absorption, compressing gross margins or undermining revenue growth if customers push back on price hikes or shift sourcing to lower-cost competitors.
  
• Prolonged underperformance and profit drag in the Engineering segment, with reliance on project timing and legacy low-margin contracts, exposes Stevanato to operating profit volatility and potential earnings headwinds if the anticipated rebound is delayed.
  
• Heavy dependence on a few large biopharma customers (especially in high-value solutions and biologics) creates customer concentration risk, where changes in purchasing patterns, inventory normalization, or supplier switching could destabilize Stevanato's revenue base.
  
• Rapid evolution of drug delivery technologies, industry consolidation, or an accelerated shift of drug manufacturing to emerging markets could structurally reduce the long-term demand for Stevanato's primary offerings (syringes, vials), erode pricing power, or limit total addressable market, impacting future revenue and margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $24.72 for Stevanato Group based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $17.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €1.5 billion, earnings will come to €244.0 million, and it would be trading on a PE ratio of 31.9x, assuming you use a discount rate of 10.4%.
• Given the current share price of $15.56, the analyst price target of $24.72 is 37.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.